Background: Genomic aberrations have been identified in metastatic castration-resistant prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known.
Introduction
Progression to lethal metastatic castration-resistant prostate cancer (mCPRC) is observed in almost all hormone sensitive prostate cancer patients treated with androgen deprivation therapy (ADT). The emergence of mCRPC has been attributed to several mechanisms including intracrine biosynthesis of androgens, expression of androgen receptor (AR) variants, activation of AR target genes by alternative steroid receptors, and evolution to an AR-null neuroendocrine phenotype [1] [2] [3] [4] . Intracrine biosynthesis of androgens can be inhibited by blocking cytochrome P450 17A1 (CYP17A1) activity with abiraterone acetate/prednisone (AA/P). AA/P slows disease progression, but many patients fail to respond suggesting primary resistance [5] . Although prospective and retrospective whole exome and transcriptome analyses have identified a number of recurrent genomic and gene expression alterations in primary and metastatic CRPC stage [2, [6] [7] [8] [9] , associations with primary or acquired AA/P resistance is unknown. We conducted a prospective study (https://clinicaltrials.gov/identifier NCT #01953640) with the aim to identify genomic alterations in metastases associated with primary and acquired resistance to AA/P.
Methods
The 'PROMOTE' (Prostate Cancer Medically Optimized GenomeEnhanced Therapy) study was initiated in May 2013 after approval by the Mayo Clinic Institutional Review Board (IRB). All enrolled patients provided written informed consent to undergo two serial metastatic tissue biopsies with the first carried out before initiation of AA/P and the second after 12 weeks of treatment. Patients had to experience progression on continuous ADT at the time of study enrollment. Full eligibility criteria are available in an abbreviated study protocol document under supplementary attachments, 'Promote Study Protocol'. The primary goal of the study was to determine genomic alterations associated with prechemotherapy AA/P treatment resistance.
Sequencing and genomic aberration analysis methods
Whole-exome sequencing (WES) was carried out on Illumina HiSeq 2500 and whole transcriptome sequencing (RNA-seq) was carried out on Illumina HiSeq 2000. Details of sequencing methods, copy number variation analysis, somatic mutation, and RNA-seq analysis along with gene pathway scores and analyses are provided under supplementary Methods, available at Annals of Oncology online.
Statistical methods
Patients showing progression after 12 weeks of AA/P treatments were categorized as 'nonresponders'. Definitions of responders and nonresponders and statistical tests used to compare the two groups are provided in supplementary Methods, available at Annals of Oncology online. Fisher's exact test was used to evaluate the association between somatic aberrations and 12-week treatment response. Cox regression models were used to assess association of gene-based pathways of AR, cell cycle progression (CCP), neuroendocrine prostate cancer (NEPC), Wnt inhibitor (25-gene panel), Wnt inhibitor (4-gene panel), and Wnt activator scores (analyzed as continuous variables) with lack of response at 12 weeks for primary resistance and with time to treatment change (TTTC) for acquired resistance.
Results

Patient and sequencing results
Between May 2013 and September 2015, 92 of 110 patients targeted for enrollment were accrued in this prospective trial of patients initiating prechemotherapy AA/P. Patient accrual was halted in September 2015, as a result of competing drug options in this stage approved after the trial began which slowed accrual. Metastatic biopsy sites included bone, lymph nodes, and soft tissues ( Figure 1A ). Tumor nucleic acid yield and purity of lymph nodal versus skeletal biopsies are shown in supplementary Figure  S1 , available at Annals of Oncology online. Of the 92 patients, 86 had analyzable RNA-seq or WES data. The biopsy sites and 12-week outcomes for these patients with analyzable RNA-seq or WES data are shown in Figure 1B . Clinical and demographic characteristics of the cohort are listed in 'Study Cohort Demographics Table' Table S3 , available at Annals of Oncology online). The mutation burden between responders and nonresponders was not different (P ¼ 0.51), although two nonresponders exhibited hypermutated genomes with over 500 nonsilent mutations (supplementary Figure S2A , available at Annals of Oncology online). The mutation burden detected in our cohort is 2.9 times higher (P < 2.2 Â 10
À16
, two-tailed Wilcoxon rank sum test) than that reported in the TCGA study (median ¼ 19, IQR: 13-25) of 333 localized, hormone-naive prostate cancer specimens [8] but 23% lower (P ¼ 9.8 Â 10
À7
) than that detected in the AACR/ PCF Stand-Up-To-Cancer (SU2C) WES study (median ¼ 71.5, IQR: 55-120) of 150 CRPC metastases [6] (supplementary Figure  S2B and D, available at Annals of Oncology online). An average of 68.9 genes (median ¼ 54, IQR: 38.5-65.5) were mutated in each tumor genome. A total of 3971 genes were detected with nonsilent mutations, of which 780 genes were recurrently mutated in two or more specimens. Consistent with previous reports, the most frequently mutated genes were TP53 (24%), MLL3 (14.7%), AR (10.7%), FOXA1 (10.7%), APC (10.7%), and SPOP (6.7%) (supplementary Table S4 , available at Annals of Oncology online) [6, 9] . Additional genes with recurrent mutations not previously reported in CRPC included TDG (12%), PSPH (10.67%), and FGFR3 (8%) (supplementary Table S5 , available at Annals of Oncology online).
We compared the 780 genes displaying recurrent mutations in our cohort (N ¼ 75) with two previously published whole-exome studies carried out in CRPC metastases [Grasso et al. [9] (N ¼ 50) and Robinson et al. (N ¼ 150) [6] ]. A set of 98 genes were mutated in all three CRPC datasets in two or more tumor specimens (supplementary Figure S3 , available at Annals of Oncology online). We then calculated MutSig-CV q-values to identify CRPC-associated significantly mutated genes (SMGs) and found 17 SMGs including TP53 and PTEN (supplementary Figure S3 and Table S15, available at Annals of Oncology online). Of the 98 genes, 10 were CRPC-specific SMGs in at least one of three CRPC cohort-based studies ( Figure 1E ; supplementary Results, available at Annals of Oncology online). Pathway analysis of the 10 genes identified 'regulation of nuclear b-catenin signaling and target gene transcription' (q-value ¼ 3.97 Â 10
À8
) suggesting a high frequency of mutations in the Wnt/b-catenin signaling pathway associated genes in CRPC. Compared with the TCGA study of hormone-naive localized prostate cancer (N ¼ 333 specimens); 85 of these 98 genes were observed to be mutated in both stages of the disease ( Figure 1F ) although the mutation frequencies were different between the three CRPC cohorts versus the TCGA cohort (supplementary Figure S3 , available at Annals of Oncology online). We detected higher mutation frequencies for AR, CDK12, CACNA1C, TNIK, DMD, VCAN, SLIT3, and NOTCH1 in CRPC patients (supplementary Figure  S3 and Table S5 , available at Annals of Oncology online).
Associations between somatic mutations and 12-week primary resistance to treatment were evaluated at the single gene level and the gene pathway/network level. Associations for each of the 744 gene mutated in two or more specimens with complete outcome data (N¼73) are provided in supplementary Table S6 , available at Annals of Oncology online. Using the risk ratio (RR) of 2 as a threshold, the 744 genes were divided into three nonoverlapping categories: 113 genes that were more frequently mutated in nonresponders (i.e. associated with primary resistance; RR > 2); 292 genes that were more frequently mutated in responders (i.e. associated with primary response; RR < 0.5); and 339 genes that were mutated at similar frequencies in both responders and nonresponders (0.5 RR 2) (supplementary Table S6 , available at Annals of Oncology online).We carried out interaction network analysis for these three groups of genes to identify 'hub' genes with hyperconnectivity to other genes. From the set of genes having similar mutational frequencies in responders and nonresponders, we can identify networks with high mutational burden in this cohort. We identified several networks with 'hub' genes (TP53, ATM, APC, MYC, and PTEN) involved in ATM-dependent DNA damage response (supplementary Figure S4A and B, available at Annals of Oncology online), and one hub gene (CSNK2A1) involved in CCP (supplementary Figure S4 , available at Annals of Oncology online). Although the genes used for this last network analysis are not limited to CRPC-specific genes, the mutation burden in these networks may contribute to CRPC stage. For genes with higher mutation frequencies in responders, we identified AR-and AKT1-centered networks. The mutation frequency of AR centered gene network in responders (24/41 ¼ 58.5%) was significantly higher compared with nonresponders (3/32 ¼ 9.4%) (P ¼ 1.9 Â 10 À5 , two-tailed Fisher's exact test), suggesting mutations in the AR regulated gene network is associated with decreased response to AA/P (supplementary Figure S5 and Table S7 , available at Annals of Oncology online). For genes with higher mutation frequencies in nonresponders, we identified a CTNNB1 (b-catenin-1) centered gene network. The mutation frequency of CTNNB1-centered gene network in non-responders (18/32 ¼ 56.25%) was higher compared with responders (7/41 ¼ 17.1%) (P ¼ 0.001, two-tailed Fisher's exact test), suggesting dysregulated Wnt/b-catenin signaling in non-responders (supplementary Figure S6 and Table S7 , available at Annals of Oncology online).
Copy number alteration and primary resistance to abiraterone acetate
We evaluated somatic copy number alterations using WES data after removing samples with tumor purity lower than 15%. This yielded samples from 22 nonresponders and 32 responders. Consistent with previous genomic analyses of CRPC, we observed frequent amplification of AR (30%) [10] , gain of 8q (50%) [11] , loss of 8p (31%), as well as deletion of RB1 (17%), CHD1 (11%), and PTEN (20%) [12] (Figure 2A and B) . The copy number alteration frequencies of AR, RB1, CHD1, and PTEN were not significantly different between responders and nonresponders (Figure 2A, supplementary Table S7 , available at Annals of Oncology online). The 6q16-22 region has been reported as the second most common genomic deletion in prostate cancer, occurring in 22%-62% of cases [13, 14] . In our cohort, 6q16-22 was deleted in 14 out of 32 (44%) responders and in 4 out of 22 (18%) nonresponders suggesting that deletion of this region is associated with response to AA/P (P ¼ 0.027) (Figure 2A and B, supplementary Table S7 , available at Annals of Oncology online).
We identified 630 and 31 genes with copy number loss occurring more frequently (P < 0.05) in nonresponders and responders, respectively ( Figure 2C , supplementary Table S8 , available at Annals of Oncology online). Similarly, we detected 79 genes with copy number gain occurring more frequently (P < 0.05) in nonresponders, but no genes were detected with copy number gain occurring more frequently in responders ( Figure 2C , supplementary Table S8 , available at Annals of Oncology online) suggesting increased genomic instability in nonresponders. Functional annotation analysis suggested that genes involved in 'negative regulation of TCF-dependent signaling by WNT ligand antagonists' (DKK4, LRP6, and SFRP2) were more frequently lost in nonresponders (q-value < 0.001) ( Figure  2A and B, supplementary Table S9 , available at Annals of Oncology online).
Gene expression signatures and primary resistance to AA/P Next, analysis of RNA-sequencing data was carried out to identify gene expression signatures associated with primary resistance to AA/P. This analysis was restricted to the 54 patients with skeletal metastases as this was the most abundant site of metastases. In these 54 patients, there were 33 responders and 21 nonresponders. Using a false discovery rate (FDR) threshold 0.01, we identified 103 genes that were up-regulated and 73 genes that were down-regulated in nonresponders ( Figure 3A , supplemen tary Table S10 , available at Annals of Oncology online). Pathway analysis using ConsensusPathDB [15] and Ingenuity Pathway Analysis (IPA) revealed that down-regulated genes in nonresponders were enriched for negative regulators of WNT signaling ( Figure 3B , supplementary Figure 3C ). On the other hand, 31 of 103 (30.0%) genes that were up-regulated in nonresponders were involved in CCP (adjusted P ¼ 9.2 Â 10
À17
). Both ConsensusPathDB and IPA identified CCP pathways as the most highly enriched pathways in nonresponders. These pathways included 'Polo-like kinase 1 (PLK1) signaling' and 'G2/M DNA damage checkpoint regulation' ( Figure 3C , supplementary Table S11, available at Annals of Oncology online). Subject_45   FBXO5  TPX2  ANLN  MKI67  ASPM  AURKA  BCAT1  BUB1  BUB1B  CDK1  CENPE  CENPF  CIT  CCNA2  CCNB1  CCNB2  DLGAP5  ESPL1  FAM83D  KIF11  KIF15  KIF23  KIF2C  KIFC1  NCAPG  NUSAP1  PLK1  PRC1  SGOL2  SMC2  TTN   WIF1 We estimated gene panel expression scores to determine correlations between biological pathways and primary resistance. These previously reported scores included an AR activity score, CCP activity score [16] , and NEPC score [17] (supplementary Methods, available at Annals of Oncology online). We detected AR activity displayed a positive albeit weak correlation with CCP (r ¼ 0.33, P ¼ 3.7 Â 10
À3
) and a negative correlation with NEPC (r ¼ À0.43, P ¼ 7.8 Â 10 À5 ) ( Figure 4A and B) . No association was observed between CCP and NEPC (r ¼ À0.0007, P ¼ 0.99) ( Figure 4C ). The positive correlation observed between AR activity and CCP is inconsistent with a recent report indicating these signatures were negatively correlated [2] . The negative correlation between AR activity and NEPC score is consistent with the observation that NEPC tumors often lose the expression of AR and AR-regulated genes such as KLK3 [18] . We found no difference in AR activity score between the responders and nonresponders (P ¼ 1, two-tailed Wilcoxon rank sum test) ( Figure 4D ). Expectedly, high CCP scores were significantly associated with nonresponders (P ¼ 0.039) ( Figure 4E ). We also noted high NEPC scores for nonresponders although with insignificant P ¼ 0.14 ( Figure 4F ). We developed a Wnt inhibitor activity (WIA) score and Wnt activator activity (WAA) score to assess the role of Wnt pathway activation in CRPC patients. WIA was calculated from four genes including WIF1, SOST, DKK1, and DKK3 that were significantly down-regulated in nonresponders ( Figure 3C ). WIA was also calculated from previously published 25 Wnt negative regulator genes [19] . The WAA score was calculated from eight genes including RSPO1/2/3/4, NDP, DACT1/2, and FRAT1. In multivariate analysis, only the CCP and WIA scores were significantly associated with primary drug resistance ( Table 1) .
Gene fusions and splicing variants associated with primary resistance
We identified 27 gene fusions (supplementary Tables S2 and S12,  available 
Efficacy of wnt and cell cycle inhibition in abiraterone-resistant organoids
Based on the clinical observations, we hypothesized that activated Wnt signaling and enhanced cell cycle activities are associated with primary resistance to AA/P. To test this hypothesis, we developed three organoid lines (MC-PRX01, MC-PRX04, and MC-PRX05). MC-PRX01 and MCPRX05 were derived from patients who were AA/P nonresponders and MCPRX-04 was derived from a patient responding to AA/P. The pretreatment tissue biopsies were grown and expanded for several generations in patient-derived xenograft tumors, and organoids were grown from these models. All the organoids displayed strong AR staining compared with LNCaP cells cultured under the same organoid conditions (supplementary Figure S7A , available at Annals of Oncology online). Genome mutational status of the organoids is summarized under supplementary Results and in supplemen tary Table S14 , available at Annals of Oncology online. The organoids were treated with the CDK4/6 inhibitor palbociclib [20, 21] or the Wnt inhibitor XAV939 [22] alone or in combination with AA/P (supplementary Figure S7B , available at Annals of Oncology online). Organoids were all pretreated with 100 nM pregnenolone, a precursor of DHEA and downstream androstenedione. This reaction is catalyzed by CYP17, the target of abiraterone acetate. As expected, pregnenolone significantly enhanced the growth of organoids (supplementary Figure S7B , available at Annals of Oncology online). Abiraterone had no effect on pregnenolone-stimulated growth indicating that the MCPRX-01 and MCPRX-05 organoids retained abiraterone resistance (supplementary Figure S7B , available at Annals of Oncology online). However, the MCPRX-04 organoid was growth-suppressed by abiraterone. Treatment with palbociclib or XAV939 as single agents or in combination with abiraterone significantly inhibited AA/P-resistant organoid growth, although the combination with either drug showed more profound growth inhibition. In contrast, palbociclib or XAV939 treatment alone or combined with abiraterone showed similar response to abiraterone alone in the MCPRX-04 organoid (supplementary Figure S7B , available at Annals of Oncology online). Collectively, these results provide a rationale for clinical trials with inhibitors of these pathways to achieve better outcomes.
Discussion
A genome-wide detailed analysis of the genomic heterogeneity of metastases carried out in this study revealed specific candidates associated with resistance to AA/P. Genes in the Wnt/b-pathway were more frequently mutated and altered expression of Wnt/bpathway components occurred more frequently in patients exhibiting primary resistance. Increased expression of CCP pathway related genes was also associated with primary resistance, as well as a shorter TTTC (acquired resistance). Mutations of the canonical Wnt/b-catenin signaling pathway have been linked to tumorigenesis and implicated in metastasis of many cancers including colon, breast, and pancreas. Links between Wnt/b-catenin signaling and therapeutic resistance have also been reported in ovarian, colon, and pancreatic cancer [23] [24] [25] . A recent study detected a higher CTNNB1 mutational frequency in CRPC patients who experienced rapid disease progression on enzalutamide therapy [26] , and another study found that noncanonical Wnt signaling is associated with enzalutamide resistance [27] . A previous study also found that a CCP score had prognostic significance for disease-specific mortality [28] . Our pathway analysis indicates that cell cycle regulation-based markers may be useful for predicting resistance to AA/P in the future. We did observe that in this metastatic CRPC cohort the detection rates of common genomic alterations (such as TP53 mutation and ETS fusions) were lower when compared with Robinson et al. [6] , but the results of genomic associations relative to disease progression do not appear to be affected by this (see detailed analysis in the supplementary Results, available at Annals of Oncology online),
Conclusions
CRPC patients with mutations or altered expression of genes in the Wnt pathway and increased CCP scores are likely to fail AA/P. Future studies will be needed to assess the feasibility of testing combination drug treatments or novel drug approaches to overcome drug resistance for such patient populations.
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Non Aberrant splicing frequency (y-axis) in CPRC patients who are responding to AA/P treatment (green), CPRC patients who are not responding to AA/P treatment (red), TCGA primary prostate cancer patients (purple), and normal prostate tissues (blue). SRPM, spliced reads per million. AA/P, abiraterone acetate/prednisone; CPRC, castration-resistant prostate cancer.
